Pfizer mulls sale of treatment portfolio worth USD 2bn, JP Morgan advising – report

Provided exclusively by Mergermarket

Pfizer (NYSE: PFE), the drug maker based in New York, is considering selling multiple drugs for cardiology, urology, and beyond with the help of JP Morgan as advisor, according to a newswire report.

The Bloomberg item, citing people familiar with the matter, said the potential divestitures could fetch up to USD 2bn from a buyer and that the company’s preference would be to sell the treatments as a single portfolio.

The report credited the people with stating that the products could appeal to either private equity firms or drugmakers, and that their combined revenue of USD 700m is 40% derived from US sales and 45% from sales in Europe.

Both Pfizer and JPMorgan declined to comment.

As seen in the mergermarket newsletter on 02/02/2017


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s